Wells Fargo & Company Raises Agilon Health (NYSE:AGL) Price Target to $1.50

Agilon Health (NYSE:AGL) had its target price upped by Wells Fargo & Company from $1.00 to $1.50 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would suggest a potential upside of 157.29% from the stock’s previous close.

AGL has been the topic of a number of other reports. Barclays cut their price objective on Agilon Health from $1.00 to $0.50 and set an “underweight” rating on the stock in a report on Friday. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a research report on Friday, December 12th. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, December 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Agilon Health has an average rating of “Hold” and an average price target of $2.60.

Agilon Health Stock Down 2.0%

Shares of AGL traded down $0.01 during mid-day trading on Friday, hitting $0.58. 2,024,525 shares of the company traded hands, compared to its average volume of 7,721,225. The company has a market capitalization of $241.87 million, a PE ratio of -0.61 and a beta of 0.06. The business has a 50 day moving average of $0.71 and a 200 day moving average of $0.86. Agilon Health has a 1-year low of $0.34 and a 1-year high of $6.08.

Agilon Health (NYSE:AGL) last released its earnings results on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 100.06% and a negative net margin of 6.60%.The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.46 billion. As a group, research analysts expect that Agilon Health will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

Hedge funds have recently modified their holdings of the company. North Peak Capital Management LLC raised its stake in Agilon Health by 10.8% during the fourth quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock worth $26,267,000 after purchasing an additional 3,715,460 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Agilon Health by 196.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock valued at $13,812,000 after buying an additional 13,283,930 shares during the period. CenterBook Partners LP raised its position in shares of Agilon Health by 492.4% during the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock valued at $11,771,000 after buying an additional 9,499,012 shares during the period. AQR Capital Management LLC lifted its holdings in Agilon Health by 1,346.6% in the fourth quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company’s stock valued at $7,033,000 after acquiring an additional 9,505,837 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Agilon Health by 30.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,019,002 shares of the company’s stock worth $5,523,000 after acquiring an additional 1,893,434 shares during the last quarter.

Trending Headlines about Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Q4 revenue beat estimates — Agilon reported $1.57B in revenue versus the $1.46B consensus, showing top-line resilience for the quarter. MarketBeat/press release
• Positive Sentiment: Company outlined a 2026 target of roughly $5.5B revenue and breakeven adjusted EBITDA, signaling management expects stabilization as it executes its transformation and disciplined contracting strategy. Seeking Alpha article
• Neutral Sentiment: Management made supporting materials available (conference call, slide deck) for investors to assess quarter details and longer-term plan execution; review these for detail on membership, margin levers and timing. Slide deck / conference call
• Negative Sentiment: Earnings miss and profitability concerns — Agilon reported a ($0.46) EPS, missing the ($0.27) consensus by $0.19 and showing a negative net margin and ROE, which fuels short-term downside pressure. MarketBeat earnings summary
• Negative Sentiment: Guidance came in below Street expectations — FY‑2026 revenue guidance ($5.4B–$5.6B) and Q1 revenue guidance missed consensus (~$6.0B and $1.5B expectations respectively), increasing execution risk and prompting investor caution. Press release / guidance
• Negative Sentiment: Analyst downgrade — Barclays cut its price target to $0.50 and set an “underweight” rating, signaling further near-term downside versus recent levels and likely contributing to selling pressure. Benzinga note
• Negative Sentiment: Multiple securities-class-action filings and many law firms are soliciting lead plaintiffs (deadline Mar. 2, 2026), raising litigation risk and potential future legal costs or settlements that can weigh on the stock. Representative notices from firms include Rosen, Schall, Pomerantz, Faruqi and others. GlobeNewswire class action notice

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.